BIOME AUSTRALIA LIMITED (BIO)
Share Price Analysis and Chart

Enter the company code or Name for stock analysis:

BIO

BIO - BIOME AUSTRALIA LIMITED

FNArena Sector : Pharmaceuticals & Biotech/Lifesciences
Year End: June
GICS Industry Group : Household & Personal Products
Debt/EBITDA: 11.04
Index:

LAST PRICE CHANGE +/- CHANGE % VOLUME

$0.54

29 Aug
2025

0.000

OPEN

$0.54

0.000

HIGH

$0.54

206,827

LOW

$0.52

TARGET
$0.95 75.9% upside
OTHER COMPANIES IN THE SAME SECTOR
1AD . ACR . ACW . ADO . AFP . AGH . AGN . ARX . AVH . BOT . CSL . CUV . DXB . EOF . GSS . HXL . IDT . IMM . IMU . IVX . LGP . MAP . MSB . MVP . MYX . NEU . NUZ . NXS . OCC . OPT . OSL . PAR . PER . PNV . PYC . RAC . RCE . SNT . SPL . TLX . TRP . VIT . ZNO .
FNARENA'S MARKET CONSENSUS FORECASTS
BIO: 1
Title FY24
Actual		 FY25
Actual		 FY26
Forecast		 FY27
Forecast
EPS (cps) xxx 0.1 1.5 xxx
DPS (cps) xxx 0.0 0.0 xxx
EPS Growth xxx N/A 100.0% xxx
DPS Growth xxx N/A N/A xxx
PE Ratio xxx N/A 34.0 xxx
Dividend Yield xxx N/A 0.0% xxx
Div Pay Ratio(%) xxx N/A N/A xxx

Dividend yield today if purchased 3 years ago: 0.00%

DIVIDEND YIELD CALCULATOR

Dividend Yield Today On Last Actual Payout :

 0.00

Estimated Dividend Growth
(Average Of Past Three Years)

  %

Amount Invested

 $ 

Tell Me The Dividend After This Many Years
Past performance is no guarantee for the future. Investors should take into account that heavy swings in share price or exceptional circumstances (a la 2009) can have a significant impact on short term calculations and averages
HISTORICAL DATA ARE ALL IN AUD
Copyright © 2025 FactSet UK Limited. All rights reserved
Title 202020212022202320242025
EPS Basic xxxxxxxxxxxxxxx0.1
DPS All xxxxxxxxxxxxxxx0.0
Sales/Revenue xxxxxxxxxxxxxxx18.4 M
Book Value Per Share xxxxxxxxxxxxxxx2.1
Net Operating Cash Flow xxxxxxxxxxxxxxx-2.8 M
Net Profit Margin xxxxxxxxxxxxxxx1.17 %

EPS Basic

DPS All

Sales/Revenue

Book Value Per Share

Net Operating Cash Flow

Net Profit Margin

Title 202020212022202320242025
Return on Capital Employed xxxxxxxxxxxxxxx5.66 %
Return on Invested Capital xxxxxxxxxxxxxxx5.51 %
Return on Assets xxxxxxxxxxxxxxx2.12 %
Return on Equity xxxxxxxxxxxxxxx5.66 %
Return on Total Capital xxxxxxxxxxxxxxx0.61 %
Free Cash Flow ex dividends xxxxxxxxxxxxxxx-2.9 M

Return on Capital Employed

Return on Invested Capital

Return on Assets

Return on Equity

Return on Total Capital

Free Cash Flow ex dividends

Title 202020212022202320242025
Short-Term Debt xxxxxxxxxxxxxxx3 M
Long Term Debt xxxxxxxxxxxxxxx0 M
Total Debt xxxxxxxxxxxxxxx3 M
Goodwill - Gross xxxxxxxxxxxxxxx-
Cash & Equivalents - Generic xxxxxxxxxxxxxxx3 M
Price To Book Value xxxxxxxxxxxxxxx21.47

Short-Term Debt

Long Term Debt

Total Debt

Goodwill - Gross

Cash & Equivalents - Generic

Price To Book Value

Title 202020212022202320242025
Capex xxxxxxxxxxxxxxx0.2 M
Capex % of Sales xxxxxxxxxxxxxxx1.09 %
Cost of Goods Sold xxxxxxxxxxxxxxx7 M
Selling, General & Admin. Exp & Other xxxxxxxxxxxxxxx11 M
Research & Development xxxxxxxxxxxxxxx-
Investments - Total xxxxxxxxxxxxxxx-

Capex

Capex % of Sales

Cost of Goods Sold

Selling, General & Admin. Exp & Other

Research & Development

Investments - Total

EXPERT VIEWS
Display All Commentary

Sentiment Indicator

1.0

No. Of Recommendations

1
BROKER DATE RATING RECOMMENDATION TARGET PRICE % TO REACH TARGET COMMENTARY

Bell Potter

28/08/2025

1

Buy

$0.95

75.93%

FY25 revenue for Biome Australia of $18.4m was an increase of 41.6% year-on-year, in line with the pre-release. International sales grew 69% and should continue to expand through new distribution partnerships, suggests Bell Potter.

Gross profit rose 42.3% and margins improved by circa 30bps, beating the analysts' forecast by 10bps. 

Costs, earnings and profit were in line with the broker's forecasts. The company delivered its maiden profit of $0.2m, though operating cash outflow of -$2.8m reflected higher inventory investment.

Biome Australia holds number two position in community pharmacy probiotics, with a revenue run rate above $20m, highlight the analysts.

New product launches and expanded international distribution are expected to lift the contribution of offshore sales to 14% by FY27.

Bell Potter makes no forecast changes. The Buy rating and 95c target are maintained.

FORECAST
Bell Potter forecasts a full year FY26 dividend of 0.00 cents and EPS of 1.50 cents.
Bell Potter forecasts a full year FY27 dividend of 0.00 cents and EPS of 3.30 cents.
Access Stockbroker Research History >
EXTRA COVERAGE
Display All Commentary

No. Of Recommendations

0

Please note: unlike Broker Call Report, BC Extra is not updated daily. The info you see might not be the latest. FNArena does its best to update ASAP.

BROKER DATE RATING RECOMMENDATION TARGET PRICE % TO REACH TARGET COMMENTARY
Access Extra Coverage Research History >

BIO STOCK CHART

FNArena News on BIO

1
FNArena Corporate Results Monitor – 28-08-2025

Aug 28 2025 - Australia
2
Rudi’s View: Best Ideas & Conviction Calls

Feb 20 2025 - Rudi's View
3
FNArena Corporate Results Monitor – 19-02-2025

Feb 19 2025 - Australia
4
Rudi’s View: AGL Energy, Bega Cheese, BRG, Harvey Norman, Imdex & Superloop

Feb 06 2025 - Rudi's View
5
Rudi’s View: Cochlear, Guzman y Gomez, SiteMinder, Wesfarmers & Xero

Jan 30 2025 - Rudi's View

Latest Pharmaceuticals & Biotech/Lifesciences News

1
Earnings Result Leaves CSL Bloodied

Aug 21 2025 - Australia
2
Renewed Momentum For CSL Shares

Jul 22 2025 - Technicals
3
Treasure Chest: CSL Not A One-Trick Pony

Jul 14 2025 - Treasure Chest
4
The Enigma Surrounding Clinuvel

Jul 03 2025 - Small Caps
5
Rudi’s View: CSL & NextDC

May 08 2025 - Rudi's View
6
Behring Margin Outlook Still Main Game For CSL

Feb 13 2025 - Australia
7
Dr Boreham’s Crucible: Arovella Therapeutics

Aug 29 2024 - Small Caps
8
ResMed’s Margin Upside Excites

Aug 07 2024 - Australia
9
Dr Boreham’s Crucible: Aroa Biosurgery

Jul 29 2024 - Small Caps
10
CSL Shares Breaking Free

Jul 23 2024 - Technicals